How Startups and Medical Experts Are Reshaping Perimenopause Care

The article explores how a coalition of tech startups, wellness advocates, and physicians is driving a surge in hormone therapy for perimenopausal women. It profiles a federal IT specialist who, after struggling with severe mood issues, discovered hormone therapy through a hiking companion and faced resistance from multiple doctors. The piece examines the growing commercial and medical ecosystem around perimenopause, including the debate over bioidentical hormones and the role of direct-to-consumer services.

The article traces how a 2002 medical study sharply curtailed hormone therapy prescriptions, as both patients and physicians came to overestimate the associated cancer risks. That historical caution created a treatment gap that telehealth companies like Midi have moved to fill, offering remote consultations and personalized dosing plans.

Schrenk's experience illustrates the friction patients can encounter: she was already taking oral contraceptives for perimenopause symptoms, yet her primary care physician and two gynecologists all declined to switch her to hormone therapy. Only through Midi's nurse practitioner did she receive the alternative treatment, which required several months of dosage adjustments before her symptoms improved.